A Randomized Controlled Trial to Compare the Safety and Efficacy of Tadalafil and Tamsulosin in Relieving Double J Stent Related Symptoms

Table 2

Ureteral stent symptom score at 1st week and 3rd week in three groups.

	Group A (Tadalafil)		-test	Group B (Tamsulosin)		-test	Group C (placebo)		-test
	1st week	3rd week		1st week	3rd week		1st week	3rd week
Urinary symptoms	40 (12–50)	20.1 (4–24)	<0.0001	42.3 (10–51)	21.8 (4.2–28)	<0.0001	43 (15–51)	42 (16–49)	0.12
Body pain	20 (4–25)	7.1 (3–14)	<0.0001	17 (3–22)	13.4 (3.9–19)	0.02	18.8 (12–22)	17 (11–20)	0.06
Sexual health	8 (2–10)	2.9 (1–5)	<0.0001	7 (2.3–11)	5.9 (1.6–9)	0.03	9 (6–10)	8.2 (4–9)	0.08
General health	23 (13–27)	19.2 (9–22)	<0.0001	22 (14–28)	19.6 (7–21)	<0.0001	25.6 (11–27)	24.9 (13–25)	0.27
Work performance	14 (4–15)	12.2 (4–14)	0.03	12 (3.3–15)	10 (4–13)	0.02	15 (12–15)	14 (11–15)	0.27
Additional problems	13 (12–18)	12.4 (3–14)	0.32	12 (3.5–20)	11.8 (3–17)	0.21	16.6 (7–18)	16.3 (8–18)	0.51
Analgesic used Diclofenac (mg)	600			1250			2200		<0.0001

Kruskal-Wallis test; values in the column with different letters indicate significant differences at .